MDXG Stock Overview
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MiMedx Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.16 |
| 52 Week High | US$9.27 |
| 52 Week Low | US$3.79 |
| Beta | 1.38 |
| 1 Month Change | -20.00% |
| 3 Month Change | -20.41% |
| 1 Year Change | 61.68% |
| 3 Year Change | -37.46% |
| 5 Year Change | 113.89% |
| Change since IPO | 20.78% |
Recent News & Updates
Recent updates
Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet
Mar 27
We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Jan 05MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 18Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?
Aug 08Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?
Apr 22Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?
Dec 20MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX
Sep 12MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range
Sep 06Is MiMedx Group (NASDAQ:MDXG) Using Too Much Debt?
Apr 12Is MiMedx Group (NASDAQ:MDXG) A Risky Investment?
Nov 30Shareholder Returns
| MDXG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.4% | -1.5% | -0.7% |
| 1Y | 61.7% | 0.1% | 22.3% |
Return vs Industry: MDXG exceeded the US Biotechs industry which returned -1% over the past year.
Return vs Market: MDXG exceeded the US Market which returned 22.8% over the past year.
Price Volatility
| MDXG volatility | |
|---|---|
| MDXG Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MDXG's share price has been volatile over the past 3 months.
Volatility Over Time: MDXG's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 895 | Joe Capper | www.mimedx.com |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
MiMedx Group, Inc. Fundamentals Summary
| MDXG fundamental statistics | |
|---|---|
| Market cap | US$909.11m |
| Earnings (TTM) | US$55.80m |
| Revenue (TTM) | US$321.48m |
16.3x
P/E Ratio2.8x
P/S RatioIs MDXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDXG income statement (TTM) | |
|---|---|
| Revenue | US$321.48m |
| Cost of Revenue | US$54.63m |
| Gross Profit | US$266.84m |
| Other Expenses | US$211.05m |
| Earnings | US$55.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.38 |
| Gross Margin | 83.01% |
| Net Profit Margin | 17.36% |
| Debt/Equity Ratio | 33.7% |
How did MDXG perform over the long term?
See historical performance and comparison